Search

Your search keyword '"MALAGUTI M"' showing total 369 results
Start Over Author "MALAGUTI M"
369 results on '"MALAGUTI M"'

2. Are the criteria for PD-MCI diagnosis comprehensive? A Machine Learning study with modified criteria

Author

Longo, C, Romano, D, Pennacchio, M, Malaguti, M, Di Giacopo, R, Giometto, B, Papagno, C, Longo C., Romano D. L., Pennacchio M., Malaguti M. C., Di Giacopo R., Giometto B., Papagno C., Longo, C, Romano, D, Pennacchio, M, Malaguti, M, Di Giacopo, R, Giometto, B, Papagno, C, Longo C., Romano D. L., Pennacchio M., Malaguti M. C., Di Giacopo R., Giometto B., and Papagno C.

Abstract

Background: Mild cognitive impairment in Parkinson's disease (PD-MCI) includes deficits in different cognitive domains, and one domain to explore for neurocognitive impairment following the DSM-V is social cognition. However, this domain is not included in current criteria for PD-MCI diagnosis. Moreover, tests vary across studies. It is, therefore, crucial to optimize cognitive assessment in PD-MCI. We aimed to do so by using Machine Learning. Methods: 275 PD patients were included. Four cognitive batteries were created: two Standard ones (Levels I and II), applying current criteria and "traditional" tests; two Alternative ones (Levels I and II), which incorporated a test of social cognition. These batteries were included in the Random Forest (RF) classifier. To assess RF performance, the AUC was considered, and the Variable Importance Index was estimated to understand the contribution of each test in PD-MCI classification. Results: Standard Level I and II showed an AUC of 0.852 and 0.892, while Alternative Level I and II showed an AUC of 0.898 and of 0.906. Variable Importance Index revealed that TMT B-A, Ekman test, RAVLT-IR, MoCA, and Action Naming were tests that most contributed to PD-MCI classification. Conclusion: The Alternative level I assessment demonstrated a similar classification capacity to the Standard level II assessment. This finding suggests that in the cognitive assessment of PD patients, it is crucial to consider the most affected cognitive domains in this clinical population, including social cognition. Taken together, these results suggest to revise current criteria for the diagnosis of PD-MCI.

Published
2024

3. Does Deep Brain Stimulation worsen cognitive decline in GBA-Parkinson Disease patients? A longitudinal study of the Italian PARKNET cohort

Author

AVENALI, M., primary, Artusi, C.A., additional, Cilia, R., additional, Giannini, G., additional, Cuconato, G., additional, Pasquini, C., additional, Albanese, A., additional, Antonini, A., additional, Bentivoglio, A.R., additional, Bove, F., additional, Bozzali, M., additional, Calandra-Buonaura, G., additional, Carelli, V., additional, Francesco, C., additional, Cocco, A., additional, Cogiamanian, F., additional, Colucci, F., additional, Cortelli, P., additional, Di Fonzo, A., additional, D'Onofrio, V., additional, Eleopra, R., additional, Elia, A.E., additional, Fioravanti, V., additional, Golfrè Andreasi, N., additional, Guerra, A., additional, Ledda, C., additional, Liccari, M., additional, Longo, C., additional, Lopiano, L., additional, Malaguti, M., additional, Mameli, F., additional, Minardi, R., additional, Monfrini, E., additional, Pacchetti, C., additional, Piano, C., additional, Rizzone, M., additional, Romito, L., additional, Sambati, L., additional, Spagnolo, F., additional, Tassorelli, C., additional, Valentino, F., additional, Valzania, F., additional, Zangaglia, R., additional, Zibetti, M., additional, and Valente, E.M., additional

Published
2024
Full Text
View/download PDF

4. Le società pubbliche e i principi del diritto della concorrenza

Author

A. GIORDANO & E. GUARNA ASSANTI, Malaguti, Maria Chiara, Salvati, Giovanna, MALAGUTI M (ORCID:0000-0003-2445-8529), SALVATI G. (ORCID:0000-0002-9931-6800), A. GIORDANO & E. GUARNA ASSANTI, Malaguti, Maria Chiara, Salvati, Giovanna, MALAGUTI M (ORCID:0000-0003-2445-8529), and SALVATI G. (ORCID:0000-0002-9931-6800)

Abstract

analisi dell'applicazione del diritto della concorrenza alle imprese pubbliche

Published
2024

5. The Modernity of the Founding Idea of Unidroit in the Contemporary World

Author

Ben Köhler, Rishi Gulati and Thomas John, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), Ben Köhler, Rishi Gulati and Thomas John, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

introduction to a book entirely devoted to the activities and instruments of UNIDROIT. PArt of a trilogy on Unidroit, Uncitral and HCCH

Published
2024

6. The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease

Author

Massy Z. A., Chesnaye N. C., Larabi I. A., Dekker F. W., Evans M., Caskey F. J., Torino C., Porto G., Szymczak M., Drechsler C., Wanner C., Jager K. J., Alvarez J. C., Schneider A., Torp A., Iwig B., Perras B., Marx C., Blaser C., Emde C., Krieter D., Fuchs D., Irmler E., Platen E., Schmidt-Gurtler H., Schlee H., Naujoks H., Schlee I., Casar S., Beige J., Rothele J., Mazur J., Hahn K., Blouin K., Neumeier K., Anding-Rost K., Schramm L., Hopf M., Wuttke N., Frischmuth N., Ichtiaris P., Kirste P., Schulz P., Aign S., Biribauer S., Manan S., Roser S., Heidenreich S., Palm S., Schwedler S., Delrieux S., Renker S., Schattel S., Stephan T., Schmiedeke T., Weinreich T., Leimbach T., Stovesand T., Bahner U., Seeger W., Cupisti A., Sagliocca A., Ferraro A., Mele A., Naticchia A., Cosaro A., Ranghino A., Stucchi A., Pignataro A., De Blasio A., Pani A., Tsalouichos A., Bellasi A., Raffaele Di Iorio B., Butti A., Abaterusso C., Somma C., D'Alessandro C., Zullo C., Pozzi C., Bergamo D., Ciurlino D., Motta D., Russo D., Favaro E., Vigotti F., Ansali F., Conte F., Cianciotta F., Giacchino F., Cappellaio F., Pizzarelli F., Greco G., Bigatti G., Marinangeli G., Cabiddu G., Fumagalli G., Caloro G., Piccoli G., Capasso G., Gambaro G., Tognarelli G., Bonforte G., Conte G., Toscano G., Del Rosso G., Capizzi I., Baragetti I., Oldrizzi L., Gesualdo L., Biancone L., Magnano M., Ricardi M., Di Bari M., Laudato M., Luisa Sirico M., Ferraresi M., Provenzano M., Malaguti M., Palmieri N., Murrone P., Cirillo P., Dattolo P., Acampora P., Nigro R., Boero R., Scarpioni R., Sicoli R., Malandra R., Savoldi S., Bertoli S., Borrelli S., Maxia S., Maffei S., Mangano S., Cicchetti T., Rappa T., Palazzo V., De Simone W., Schrander A., Van Dam B., Siegert C., Gaillard C., Beerenhout C., Verburgh C., Janmaat C., Hoogeveen E., Hoorn E., Boots J., Boom H., Eijgenraam J. -W., Kooman J., Rotmans J., Vogt L., Raasveld M., Vervloet M., Van Buren M., Van Diepen M., Leurs P., Voskamp P., Blankestijn P., Van Esch S., Boorsma S., Berger S., Konings C., Aydin Z., Musiala A., Szymczak A., Olczyk E., Augustyniak-Bartosik H., Miskowiec-Wisniewska I., Manitius J., Pondel J., Jedrzejak K., Nowanska K., Nowak L., Durlik M., Dorota S., Nieszporek T., Heleniak Z., Jonsson A., Blom A. -L., Rogland B., Wallquist C., Vargas D., Dimeny E., Sundelin F., Uhlin F., Welander G., Bascaran Hernandez I., Grontoft K. -C., Stendahl M., Svensson M., Heimburger O., Kashioulis P., Melander S., Almquist T., Jensen U., Woodman A., McKeever A., Ullah A., McLaren B., Harron C., Barrett C., O'Toole C., Summersgill C., Geddes C., Glowski D., McGlynn D., Sands D., Roy G., Hirst G., King H., McNally H., Masri-Senghor H., Murtagh H., Rayner H., Turner J., Wilcox J., Berdeprado J., Wong J., Banda J., Jones K., Haydock L., Wilkinson L., Carmody M., Weetman M., Joinson M., Dutton M., Matthews M., Morgan N., Bleakley N., Cockwell P., Roderick P., Mason P., Kalra P., Sajith R., Chapman S., Navjee S., Crosbie S., Brown S., Tickle S., Mathavakkannan S., Kuan Y., Massy, Z. A., Chesnaye, N. C., Larabi, I. A., Dekker, F. W., Evans, M., Caskey, F. J., Torino, C., Porto, G., Szymczak, M., Drechsler, C., Wanner, C., Jager, K. J., Alvarez, J. C., Schneider, A., Torp, A., Iwig, B., Perras, B., Marx, C., Blaser, C., Emde, C., Krieter, D., Fuchs, D., Irmler, E., Platen, E., Schmidt-Gurtler, H., Schlee, H., Naujoks, H., Schlee, I., Casar, S., Beige, J., Rothele, J., Mazur, J., Hahn, K., Blouin, K., Neumeier, K., Anding-Rost, K., Schramm, L., Hopf, M., Wuttke, N., Frischmuth, N., Ichtiaris, P., Kirste, P., Schulz, P., Aign, S., Biribauer, S., Manan, S., Roser, S., Heidenreich, S., Palm, S., Schwedler, S., Delrieux, S., Renker, S., Schattel, S., Stephan, T., Schmiedeke, T., Weinreich, T., Leimbach, T., Stovesand, T., Bahner, U., Seeger, W., Cupisti, A., Sagliocca, A., Ferraro, A., Mele, A., Naticchia, A., Cosaro, A., Ranghino, A., Stucchi, A., Pignataro, A., De Blasio, A., Pani, A., Tsalouichos, A., Bellasi, A., Raffaele Di Iorio, B., Butti, A., Abaterusso, C., Somma, C., D'Alessandro, C., Zullo, C., Pozzi, C., Bergamo, D., Ciurlino, D., Motta, D., Russo, D., Favaro, E., Vigotti, F., Ansali, F., Conte, F., Cianciotta, F., Giacchino, F., Cappellaio, F., Pizzarelli, F., Greco, G., Bigatti, G., Marinangeli, G., Cabiddu, G., Fumagalli, G., Caloro, G., Piccoli, G., Capasso, G., Gambaro, G., Tognarelli, G., Bonforte, G., Conte, G., Toscano, G., Del Rosso, G., Capizzi, I., Baragetti, I., Oldrizzi, L., Gesualdo, L., Biancone, L., Magnano, M., Ricardi, M., Di Bari, M., Laudato, M., Luisa Sirico, M., Ferraresi, M., Provenzano, M., Malaguti, M., Palmieri, N., Murrone, P., Cirillo, P., Dattolo, P., Acampora, P., Nigro, R., Boero, R., Scarpioni, R., Sicoli, R., Malandra, R., Savoldi, S., Bertoli, S., Borrelli, S., Maxia, S., Maffei, S., Mangano, S., Cicchetti, T., Rappa, T., Palazzo, V., De Simone, W., Schrander, A., Van Dam, B., Siegert, C., Gaillard, C., Beerenhout, C., Verburgh, C., Janmaat, C., Hoogeveen, E., Hoorn, E., Boots, J., Boom, H., Eijgenraam, J. -W., Kooman, J., Rotmans, J., Vogt, L., Raasveld, M., Vervloet, M., Van Buren, M., Van Diepen, M., Leurs, P., Voskamp, P., Blankestijn, P., Van Esch, S., Boorsma, S., Berger, S., Konings, C., Aydin, Z., Musiala, A., Szymczak, A., Olczyk, E., Augustyniak-Bartosik, H., Miskowiec-Wisniewska, I., Manitius, J., Pondel, J., Jedrzejak, K., Nowanska, K., Nowak, L., Durlik, M., Dorota, S., Nieszporek, T., Heleniak, Z., Jonsson, A., Blom, A. -L., Rogland, B., Wallquist, C., Vargas, D., Dimeny, E., Sundelin, F., Uhlin, F., Welander, G., Bascaran Hernandez, I., Grontoft, K. -C., Stendahl, M., Svensson, M., Heimburger, O., Kashioulis, P., Melander, S., Almquist, T., Jensen, U., Woodman, A., Mckeever, A., Ullah, A., Mclaren, B., Harron, C., Barrett, C., O'Toole, C., Summersgill, C., Geddes, C., Glowski, D., Mcglynn, D., Sands, D., Roy, G., Hirst, G., King, H., Mcnally, H., Masri-Senghor, H., Murtagh, H., Rayner, H., Turner, J., Wilcox, J., Berdeprado, J., Wong, J., Banda, J., Jones, K., Haydock, L., Wilkinson, L., Carmody, M., Weetman, M., Joinson, M., Dutton, M., Matthews, M., Morgan, N., Bleakley, N., Cockwell, P., Roderick, P., Mason, P., Kalra, P., Sajith, R., Chapman, S., Navjee, S., Crosbie, S., Brown, S., Tickle, S., Mathavakkannan, S., Kuan, Y., Nephrology, ACS - Diabetes & metabolism, Medical Informatics, APH - Methodology, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, APH - Health Behaviors & Chronic Diseases, and ACS - Pulmonary hypertension & thrombosis

Subjects
Transplantation, Nephrology, uremic toxins, CKD, symptoms, symptom, elderly
Abstract

Background Patients with stage 4/5 chronic kidney disease (CKD) suffer from various symptoms. The retention of uremic solutes is thought to be associated with those symptoms. However, there are relatively few rigorous studies on the potential links between uremic toxins and symptoms in patients with CKD. Methods The EQUAL study is an ongoing observational cohort study of non-dialyzed patients with stage 4/5 CKD. EQUAL patients from Germany, Poland, Sweden and the UK were included in the present study (n = 795). Data and symptom self-report questionnaires were collected between April 2012 and September 2020. Baseline uric acid and parathyroid hormone and 10 uremic toxins were quantified. We tested the association between uremic toxins and symptoms and adjusted P-values for multiple testing. Results Symptoms were more frequent in women than in men with stage 4/5 CKD, while levels of various uremic toxins were higher in men. Only trimethylamine N-oxide (TMAO; positive association with fatigue), p-cresyl sulfate (PCS) with constipation and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (negative association with shortness of breath) demonstrated moderately strong associations with symptoms in adjusted analyses. The association of phenylacetylglutamine with shortness of breath was consistent in both sexes, although it only reached statistical significance in the full population. In contrast, TMAO (fatigue) and PCS and phenylacetylglutamine (constipation) were only associated with symptoms in men, who presented higher serum levels than women. Conclusion Only a limited number of toxins were associated with symptoms in persons with stage 4/5 CKD. Other uremic toxins, uremia-related factors or psychosocial factors not yet explored might contribute to symptom burden.

Published
2022
Full Text
View/download PDF

7. The Independence and Impartiality of Adjudicators at the World Trade Organization

Author

Cordero Moss G, Malaguti, Maria Chiara, Poli, G, MALAGUTI M (ORCID:0000-0003-2445-8529), Cordero Moss G, Malaguti, Maria Chiara, Poli, G, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

analysis of the specificities of adjudicatory means and mechanisms in WTO. To use as benchmark for a new international court for investment arbitration

Published
2023

8. Moderate wine consumption and health: a narrative review

Author

Hrelia, S., DI RENZO, L., Bavaresco, Luigi, Bernardi, Evelina, Malaguti, Maria Chiara, Giacosa, A., BAVARESCO L. (ORCID:0000-0002-1278-6587), BERNARDI E., MALAGUTI M. (ORCID:0000-0003-2445-8529), Hrelia, S., DI RENZO, L., Bavaresco, Luigi, Bernardi, Evelina, Malaguti, Maria Chiara, Giacosa, A., BAVARESCO L. (ORCID:0000-0002-1278-6587), BERNARDI E., and MALAGUTI M. (ORCID:0000-0003-2445-8529)

Abstract

Although it is clearly established that the abuse of alcohol is seriously harmful to health, many epidemiological and clinical evidences seem to underline the protective role of moderate quantities of alcohol and in particular of wine on health. This review aims to re-evaluate the relationship between the type and dose of alcoholic drink and reduced or increased risk of various diseases, in the light of the most current scientific evidence. In particular in vitro studies on the modulation of biochemical pathways and gene expression of wine bioactive components together with in vivo studies on cardiovascular pathologies, type 2 diabetes, neurological degenerative diseases and longevity were carefully evaluated. A brief discussion on oenological practices potentially affecting bioactive components content in wine is included. The analysis clearly indicates that wine differs from other alcoholic beverages and its moderate consumption not only does not increase the risk of chronic degenerative diseases but is also associated with health benefits particularly when included in a Mediterranean diet model. Obviously, every effort must be made to promote behavioral education to prevent abuse, especially among young people.

Published
2023

9. Clinical profile and in-hospital outcome of patients supported by intra-aortic balloon pump in the clinical setting of cardiogenic shock according to aetiology

Author

Garofalo, M, primary, Corsini, A, additional, Potena, L, additional, Schinzari, M, additional, Nardi, E, additional, Barberini, F, additional, Gargiulo, C, additional, Malaguti, M, additional, Sabatino, M, additional, Semprini, F, additional, Galie, N, additional, and Nanni, S, additional

Published
2022
Full Text
View/download PDF

10. Facial expressions recognition and discrimination in Parkinson’s disease

Author

Mattavelli, G, Barvas, E, Longo, C, Zappini, F, Ottaviani, D, Malaguti, M, Pellegrini, M, Papagno, C, Mattavelli G., Barvas E., Longo C., Zappini F., Ottaviani D., Malaguti M. C., Pellegrini M., Papagno C., Mattavelli, G, Barvas, E, Longo, C, Zappini, F, Ottaviani, D, Malaguti, M, Pellegrini, M, Papagno, C, Mattavelli G., Barvas E., Longo C., Zappini F., Ottaviani D., Malaguti M. C., Pellegrini M., and Papagno C.

Abstract

Emotion processing impairment is a common non-motor symptom in Parkinson’s Disease (PD). Previous literature reported conflicting results concerning, in particular, the performance for different emotions, the relation with cognitive and neuropsychiatric symptoms and the affected stage of processing. This study aims at assessing emotion recognition and discrimination in PD. Recognition of six facial expressions was studied in order to clarify its relationship with motor, cognitive and neuropsychiatric symptoms. Sensitivity in discriminating happy and fearful faces was investigated to address controversial findings on impairment in early stages of emotion processing. To do so, seventy PD patients were tested with the Ekman 60 Faces test and compared with 46 neurologically unimpaired participants. Patients’ performances were correlated with clinical scales and neuropsychological tests. A subsample of 25 PD patients and 25 control participants were also tested with a backward masking paradigm for sensitivity in happiness and fear discrimination. Results showed that PD patients were impaired in facial emotion recognition, especially for fearful expressions. The performance correlated with perceptual, executive and general cognitive abilities, but facial expression recognition deficits were present even in cognitively unimpaired patients. In contrast, patients’ sensitivity in backward masking tasks was not reduced as compared to controls. Taken together our data demonstrate that facial emotion recognition, and fear expression in particular, is critically affected by neurodegeneration in PD and related to cognitive abilities; however, it appears before other cognitive impairments. Preserved performances in discriminating shortly presented facial expressions, suggest unimpaired early stages of emotion processing.

Published
2021

11. L’Euro e i mercati monetari nel pensiero di Alberto Predieri

Author

MORBIDELLI G, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), MORBIDELLI G, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

In un volume sul pensiero di Alberto Predieri, considerazioni sui suoi ultimi scritti premonitori su Unione Monetaria e mercati finanziari internazionali

Published
2022

12. Cenni introduttivi su aspetti transnazionali commerciali

Author

TANZI A, CHIUSSI CURZI L, FARNELLI GM, MENSI A, Malaguti, Maria Chiara, Malatesta, A, MALAGUTI M (ORCID:0000-0003-2445-8529), TANZI A, CHIUSSI CURZI L, FARNELLI GM, MENSI A, Malaguti, Maria Chiara, Malatesta, A, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

various aspects and effects of the transition to renevable on international commerce

Published
2022

13. New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: A multicohort observational study

Author

Minutolo, R., Provenzano, M., Chiodini, P., Borrelli, S., Garofalo, C., Andreucci, M., Liberti, M. E., Bellizzi, V., Conte, G., De Nicola, L., Zamboli, P., Iodice, F. C., Signoriello, S., Gallo, C., Cianciaruso, B., Pota, A., Nappi, F., Avella, F., Di Iorio, B. R., Cestaro, R., Martignetti, V., Morrone, L., Lupo, A., Abaterusso, C., Donadio, C., Bonomini, M., Sirolli, V., Casino, F., Lopez, T., Detomaso, F., Giannattasio, M., Virgilio, M., Tarantino, G., Cristofano, C., Tuccillo, S., Chimienti, S., Petrarulo, F., Giancaspro, V., Strippoli, M., Laraia, E., Gallucci, M., Gigante, B., Lodeserto, C., Santese, D., Montanaro, A., Giordano, R., Caglioti, A., Fuiano, G., Zoccali, C., Caridi, G., Postorino, M., Savica, V., Monardo, P., Bellinghieri, G., Santoro, D., Castellino, P., Rapisarda, F., Fatuzzo, P., Messina, A., Dal Canton, A., Esposito, V., Formica, M., Segoloni, G., Gallieni, M., Locatelli, F., Tarchini, R., Meneghel, G., Oldrizzi, L., Cossu, M., Di Giulio, S., Malaguti, M., Pizzarelli, F., Quintaliani, G., Pisani, A., Bonofiglio, R., Grandaliano, Giuseppe, Russo, D., Di Micco, L., Torraca, S., Sabbatini, M., Grandaliano G. (ORCID:0000-0003-1213-2177), Minutolo, R., Provenzano, M., Chiodini, P., Borrelli, S., Garofalo, C., Andreucci, M., Liberti, M. E., Bellizzi, V., Conte, G., De Nicola, L., Zamboli, P., Iodice, F. C., Signoriello, S., Gallo, C., Cianciaruso, B., Pota, A., Nappi, F., Avella, F., Di Iorio, B. R., Cestaro, R., Martignetti, V., Morrone, L., Lupo, A., Abaterusso, C., Donadio, C., Bonomini, M., Sirolli, V., Casino, F., Lopez, T., Detomaso, F., Giannattasio, M., Virgilio, M., Tarantino, G., Cristofano, C., Tuccillo, S., Chimienti, S., Petrarulo, F., Giancaspro, V., Strippoli, M., Laraia, E., Gallucci, M., Gigante, B., Lodeserto, C., Santese, D., Montanaro, A., Giordano, R., Caglioti, A., Fuiano, G., Zoccali, C., Caridi, G., Postorino, M., Savica, V., Monardo, P., Bellinghieri, G., Santoro, D., Castellino, P., Rapisarda, F., Fatuzzo, P., Messina, A., Dal Canton, A., Esposito, V., Formica, M., Segoloni, G., Gallieni, M., Locatelli, F., Tarchini, R., Meneghel, G., Oldrizzi, L., Cossu, M., Di Giulio, S., Malaguti, M., Pizzarelli, F., Quintaliani, G., Pisani, A., Bonofiglio, R., Grandaliano, Giuseppe, Russo, D., Di Micco, L., Torraca, S., Sabbatini, M., and Grandaliano G. (ORCID:0000-0003-1213-2177)

Abstract

Background: Anemia is a common complication of chronic kidney disease (CKD), but its incidence in nephrology settings is poorly investigated. Similarly, the risks of adverse outcomes associated with new-onset anemia are not known. Methods: We performed a pooled analysis of three observational cohort studies including 1031 non-anemic CKD patients with eGFR <60 mL/min/1.73 m2 regularly followed in renal clinics. We estimated the incidence of mild anemia (hemoglobin 11-12 g/dL in women and 11-13 g/dL in men) and severe anemia (hemoglobin <11 g/dL or use of erythropoiesis-stimulating agents) during a 3-year follow-up period. Thereafter we estimated the risk of end-stage kidney disease (ESKD) and all-cause death associated with new-onset mild and severe anemia. Results: The mean age was 63 ± 14 years, 60% were men and 20% had diabetes. The mean estimated glomerular filtration rate (eGFR) was 37 ± 13 mL/min/1.73 m2 and the median proteinuria was 0.4 g/day [interquartile range (IQR) 0.1-1.1]. The incidence of mild and severe anemia was 13.7/100 patients-year and 6.2/100 patients-year, respectively. Basal predictors of either mild or severe anemia were diabetes, lower hemoglobin, higher serum phosphate, eGFR <30 mL/min/1.73 m2 and proteinuria >0.50 g/day. Male sex, moderate CKD (eGFR 30-44 mL/min/1.73 m2) and moderate proteinuria (0.15-0.50 g/day) predicted only mild anemia. The incidence of anemia increased progressively with CKD stages (from 8.77 to 76.59/100 patients-year) and the proteinuria category (from 13.99 to 25.02/100 patients-year). During a median follow-up of 3.1 years, 232 patients reached ESKD and 135 died. Compared with non-anemic patients, mild anemia was associated with a higher adjusted risk of ESKD {hazard ratio [HR] 1.42 [95% confidence interval (CI) 1.02-1.98]} and all-cause death [HR 1.55 (95% CI 1.04-2.32)]. Severe anemia was associated with an even higher risk of ESKD [HR 1.73 (95% CI 1.20-2.51)] and death [HR 1.83 (95% CI 1.05-3.19)].

Published
2022

14. Deficits in Emotion Recognition and Theory of Mind in Parkinson’s Disease Patients With and Without Cognitive Impairments

Author

Dodich, A, Funghi, G, Meli, C, Pennacchio, M, Longo, C, Malaguti, M, Di Giacopo, R, Zappini, F, Turella, L, Papagno, C, Dodich, Alessandra, Funghi, Giulia, Meli, Claudia, Pennacchio, Maria, Longo, Chiara, Malaguti, Maria Chiara, Di Giacopo, Raffaella, Zappini, Francesca, Turella, Luca, Papagno, Costanza, Dodich, A, Funghi, G, Meli, C, Pennacchio, M, Longo, C, Malaguti, M, Di Giacopo, R, Zappini, F, Turella, L, Papagno, C, Dodich, Alessandra, Funghi, Giulia, Meli, Claudia, Pennacchio, Maria, Longo, Chiara, Malaguti, Maria Chiara, Di Giacopo, Raffaella, Zappini, Francesca, Turella, Luca, and Papagno, Costanza

Abstract

Background: Emotion recognition and social deficits have been previously reported in Parkinson’s disease (PD). However, the extent of these impairments is still unclear and social cognition is excluded from the cognitive domains considered in the current criteria for PD mild cognitive impairment (MCI). This study aims to analyze emotion recognition, affective and cognitive theory of mind in early PD patients classified according to Level II MCI criteria, and to evaluate the prevalence of socio-cognitive deficits in this sample. Methods: We enrolled 45 participants with PD, classified as cognitively unimpaired (CU; n = 32) or MCI (n = 13) based on a standard neuropsychological assessment. Social cognitive skills were evaluated through validated tests for emotion recognition (i.e., Ekman 60-faces test, Ek60 Test) and mental states attribution (Story-based Empathy Task, SET) and compared to a group of 45 healthy controls (HC). Between-group differences in social tasks were performed, as well as correlation analyses to assess the relationship between social, cognitive, and clinical variables. Finally, the number of patients with social cognitive impairments in both MCI and CU subgroups was computed based on Italian normative data. Results: Statistical comparison revealed significant differences among groups in the Ek60 test, with MCI obtaining significantly lower scores than HC and CU, especially for negative emotions. Significant differences were detected also in the SET, with lower performance in emotion and intention attribution for both PD groups compared to HC. A significant correlation emerged between the Ek60 test and emotion attribution. Nine patients showed poor performance at social tasks, five of them being classified as PD-CU. Discussion: Parkinson’s disease cognitive profile was characterized by emotion recognition and attribution deficits. These results, as well as the detection of CU patients with isolated socio-cognitive impairments, underline the import

Published
2022

16. Fintech e piattaforme digitali nel settore finanziario tra concorrenza e regolazione

Author

AA VV, FINOCCHIARO G,, SALCE V, Malaguti, M, MALAGUTI M (ORCID:0000-0003-2445-8529), AA VV, FINOCCHIARO G,, SALCE V, Malaguti, M, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

the contribution explains why competition and regulation overlap in the case of fintech and how technology has changed the market so changing also the instruments for regulation

Published
2019

20. Die Architektur des internationalen Wirtschaftsrechts Grundlagen und Ausblicke

Author

Mazzoni, Elisabetta Maria, Malaguti, Maria Chiara, MAZZONI M, MALAGUTI M (ORCID:0000-0003-2445-8529), Mazzoni, Elisabetta Maria, Malaguti, Maria Chiara, MAZZONI M, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

storia del commerciointernazionale e sue modifiche in base alle teorie giuridiche ed economiche. Bretton Woods e la sua crisi

Published
2021

21. Derecho del Comercio Internacional – Fundamentos y Perspectivas

Author

Mazzoni, Alberto, Malaguti, Maria Chiara, MAZZONI A, MALAGUTI M (ORCID:0000-0003-2445-8529), Mazzoni, Alberto, Malaguti, Maria Chiara, MAZZONI A, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

history of trade law and changes according to legal and economic theories in the years. Lex mercatoria and public international law. Current challenges

Published
2021

24. Prospettive dell'arbitrato degli investimenti (CAp 33)

Author

MANTUCCI D, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), MANTUCCI D, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

perspectives of recent reforms of ISDS in the light specifically of the works of WG III UNCITRAL

Published
2021

25. Chapter 2 – Legal and regulatory history of EU retail payments

Author

RUSSO D, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), RUSSO D, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

history of regulation of payment systems and services in the EU. A paradigm for international and domestic regulation

Published
2021

26. Meripilus giganteus ethanolic extract exhibits pro-apoptotic and anti-proliferative effects in leukemic cell lines

Author

Lenzi M, Cocchi V, Barbalace Maria Cristina, Angeloni C, Hrelia P, Malaguti M, Hrelia S, and Lenzi M, Cocchi V, Barbalace Maria Cristina , Angeloni C , Hrelia P, Malaguti M, Hrelia S

Subjects
Meripilus giganteus, Cytotoxicity, Apoptosis, Chemoprevention, Flow-cytometry, Leukemic cell lines
Abstract

BACKGROUND: The interest towards botanicals and plant extracts has strongly risen due to their numerous biological effects and ability to counteract chronic diseases development. Among these effects, chemoprevention which represents the possibility to counteract the cancerogenetic process is one of the most studied. The extracts of mushroom Meripilus giganteus (MG) (Phylum of Basidiomycota) showed to exert antimicrobic, antioxidant and antiproliferative effects. Therefore, since its effect in leukemic cell lines has not been previously evaluated, we studied its potential chemopreventive effect in Jurkat and HL-60 cell lines. METHODS: MG ethanolic extract was characterized for its antioxidant activity and scavenging effect against different radical species. Moreover, its phenolic profile was evaluated by HPLC-MS-MS analyses. Flow cytometry (FCM) analyses of Jurkat and HL-60 cells treated with MG extract (0-750μg/mL) for 24-72h- allowed to evaluate its cytotoxicity, pro-apoptotic and anti-proliferative effect. To better characterize MG pro-apoptotic mechanism ROS intracellular level and the gene expression level of FAS, BAX and BCL2 were also evaluated. Moreover, to assess MG extract selectivity towards cancer cells, its cytotoxicity was also evaluated in human peripheral blood lymphocytes (PBL). RESULTS: MG extract induced apoptosis in Jurkat and HL-60 cells in a dose- and time- dependent manner by increasing BAX/BCL2 ratio, reducing ROS intracellular level and inducing FAS gene expression level. In fact, reduced ROS level is known to be related to the activation of apoptosis in leukemic cells by the involvement of death receptors. MG extract also induced cell-cycle arrest in HL-60 cells. Moreover, IC50 at 24h treatment resulted 2 times higher in PBL than in leukemic cell lines. CONCLUSIONS: Our data suggest that MG extract might be considered a promising and partially selective chemopreventive agent since it is able to modulate different mechanisms in transformed cells at concentrations lower than in non-transformed ones.

Published
2019

27. Role of quercetin in modulating rat cardiomyocyte gene expression profile

Author

Angeloni, C., Leoncini, E., Malaguti, M., Angelini, S., Hrelia, P., and Hrelia, S.

Subjects
Quercetin -- Physiological aspects, Quercetin -- Health aspects, Quercetin -- Genetic aspects, Heart muscle -- Properties, Heart muscle -- Genetic aspects, Heart muscle -- Health aspects, Muscle cells -- Genetic aspects, Muscle cells -- Health aspects, Oxidative stress -- Prevention, Biological sciences
Abstract

Despite extensive studies, the fundamental mechanisms responsible for the development and progression of cardiovascular diseases have not yet been fully elucidated. Recent experimental and clinical studies have suggested that reactive oxygen species play a major pathological role. Oxidative stress reduction induced by flavonoids has been regarded by many as the most likely mechanism in the protective effects of these compounds; however, there is an emerging view that flavonoids may also exert modulatory actions on protein kinase and lipid kinase signaling pathways. Quercetin, a major flavonoid present in the human diet, has been widely studied, and its biological properties are consistent with its protective role in the cardiovascular system. However, it remains unknown whether the cardioprotective effects of quercetin may also occur through the modulation of genes involved in cell survival. The main goal of this study was to examine the gene expression profiling of cultured rat primary cardiomyocytes treated with quercetin using DNA microarrays and to relate these data to functional effects. Results showed distinct temporal changes in gene expression induced by quercetin and a strong upregulation of phase 2 enzymes, highlighting quercetin ability to act also with an indirect antioxidant mechanism. flavonoids; phase 2 enzymes; oxidative stress

Published
2008

28. GBA-Related Parkinson’s Disease:Dissection of Genotype–Phenotype Correlates in a LargeItalian Cohort

Author

Petrucci, S., Ginevrino, M., Trezzi, I., Monfrini, E., Ricciardi, L., Albanese, A., Avenali, M., Barone, P., Bentivoglio, A. R., Bonifati, V., Bove, F., Bonanni, L., Brusa, L., Cereda, C., Cossu, G., Criscuolo, C., Dati, G., De Rosa, A., Eleopra, R., Fabbrini, G., Fadda, L., Garbellini, M., Minafra, B., Onofrj, M., Pacchetti, C., Palmieri, I., Pellecchia, M. T., Petracca, M., Picillo, M., Pisani, A., Vallelunga, A., Zangaglia, R., Di Fonzo, A., Morgante, F., Valente, E. M., Altavista, M. C., Amboni, M., Ardolino, G., Berardelli, A., Cogiamanian, F., Colosimo, C., Costanti, D., De Michele, G., Bonaventura, C. D., Di Lazzaro, G., Di Lazzaro, V., Emanuele Elia, A., Erro, R., Ferrazzano, G., Guerra, A., Ialongo, T., Malaguti, M. C., Melis, M., Moro, E., Oppo, V., Ottaviani, D., Peluso, S., Quadri, M. L., Romito, L. M., Sarchioto, M., Schirinzi, T., Sorbera, C., Stefani, A., Thomas, A., Valente, M. L., Volpe, G, ITA-GENE-PD Study, Group., Petrucci, S, Ginevrino, M, Trezzi, I, Monfrini, E, Ricciardi, L, Albanese, A, Avenali, M, Barone, P, Bentivoglio, Ar, Bonifati, V, Bove, F, Bonanni, L, Brusa, L, Cereda, C, Cossu, G, Criscuolo, C, Dati, G, De Rosa, A, Eleopra, R, Fabbrini, G, Fadda, L, Garbellini, M, Minafra, B, Onofrj, M, Pacchetti, C, Palmieri, I, Pellecchia, Mt, Petracca, M, Picillo, M, Pisani, A, Vallelunga, A, Zangaglia, R, Di Fonzo, A, Morgante, F, Valente, Em, Clinical Genetics, Erasmus MC other, and Radiology & Nuclear Medicine

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Parkinson's disease, Genotype, genotype–phenotype correlates, Disease, Settore MED/05, Genotype phenotype, dementia, GBA, impulsive–compulsive behavior, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Internal medicine, medicine, Dementia, Humans, Sanger sequencing, business.industry, Dissection, Parkinson Disease, medicine.disease, Phenotype, Settore MED/26 - NEUROLOGIA, 030104 developmental biology, Glucosylceramidase, Italy, Mutation, Neurology, Cohort, symbols, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

BACKGROUND Variants in GBA are the most common genetic risk factor for Parkinson's disease (PD). The impact of different variants on the PD clinical spectrum is still unclear. OBJECTIVES We determined the frequency of GBA-related PD in Italy and correlated GBA variants with motor and nonmotor features and their occurrence over time. METHODS Sanger sequencing of the whole GBA gene was performed. Variants were classified as mild, severe, complex, and risk. β-glucocerebrosidase activity was measured. The Kaplan-Meier method and Cox proportional hazard regression models were performed. RESULTS Among 874 patients with PD, 36 variants were detected in 14.3%, including 20.4% early onset. Patients with GBA-PD had earlier and more frequent occurrence of several nonmotor symptoms. Patients with severe and complex GBA-PD had the highest burden of symptoms and a higher risk of hallucinations and cognitive impairment. Complex GBA-PD had the lowest β-glucocerebrosidase activity. CONCLUSIONS GBA-PD is highly prevalent in Italy. Different types of mutations underlie distinct phenotypic profiles. © 2020 International Parkinson and Movement Disorder Society.

Published
2020

30. Il divieto di aiuti di Stato (Cap. V)

Author

GIORDANO A, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), GIORDANO A, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

EU State aids in the theory of fiscal law

Published
2020

34. Nutraceutici ad azione protettiva sul sistema cardiovascolare: il ruolo degli estratti di foglie di olivo e di biancospino

Author

Malaguti M, Hrelia S, Malaguti M, and Hrelia S

Subjects
Olea Europea, Biancospino, Pressione Arteriosa
Abstract

L’elenco dei “botanicals” per i quali è ammesso, in accordo alle Linee guida ministeriali di riferimento, indicare l’effetto fisiologico “Regolarità della pressione arteriosa” sono numerosi e comprendono diverse parti di alcuni vegetali. Alcune di queste come le foglie di Olea Europea (OLE) e gli estratti di Crataegus Oxyacantha (Biancospino) sono state particolarmente studiate per gli effetti sulla pressione arteriosa e, più in generale per quelli protettivi nei confronti delle patologie cardiovascolari. Obiettivo della presente revisione sarà quindi quello di descrivere l’azione biologica degli estratti di OLE e Biancospino partendo dagli impieghi tradizionali, addentrandosi poi, quanto più possibile, nei meccanismi biologici responsabili degli effetti descritti ed arrivando a descrivere gli studi clinici che abbiano valutato tali effetti sull’uomo.

Published
2018

43. Conversione forzosa di titoli di Stato e tutele del creditore nel diritto dell'Unione: tra immunità dalla giurisdizione dello STato e natura non commerciale della materia

Author

ZANOBETTI A et alteri, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), ZANOBETTI A et alteri, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

how State obligations under domestic law coexist with sovereign powers on monetary policy. Private law and public law

Published
2019

44. Isolation and Characterization of Wheat Derived Nonspecific Lipid Transfer Protein 2 (nsLTP2)

Author

Bosi S, Fiori J, Dinelli G, Rigby N, Leoncini E, Prata C, Bregola V, Marotti I, Gotti R, Naldi M, Massaccesi L, Malaguti M, Kroon P, Hrelia S, and Bosi S, Fiori J, Dinelli G, Rigby N, Leoncini E, Prata C, Bregola V, Marotti I, Gotti R, Naldi M, Massaccesi L, Malaguti M, Kroon P, Hrelia S

Subjects
L-Lactate Dehydrogenase, antioxidant activity, Endothelial Cells, Antioxidants, Oxidative Stress, cytoprotection, bioactive peptide, Dietary Supplements, Human Umbilical Vein Endothelial Cells, Humans, triticum aestivum, nsLTP2, Carrier Proteins, Reactive Oxygen Species, Chromatography, High Pressure Liquid, Triticum, Plant Proteins
Abstract

Numerous studies support the protective role of bioactive peptides against cardiovascular diseases. Cereals represent the primary source of carbohydrates, but they also contain substantial amounts of proteins, therefore representing a potential dietary source of bioactive peptides with nutraceutical activities. The analysis of wheat extracts purified by chromatographic techniques by means of HPLC-UV/nanoLC-nanoESI-QTOF allowed the identification of a signal of about 7 kDa which, following data base searches, was ascribed to a nonspecific lipid-transfer protein (nsLTP) type 2 from Triticum aestivum (sequence coverage of 92%). For the first time nsLTP2 biological activities have been investigated. In particular, in experiments with human umbilical vein endothelial cells (HUVEC), nsLTP2 displayed antioxidant and cytoprotective activities, being able to significantly decrease reactive oxygen species (ROS) levels and to reduce lactate dehydrogenase (LDH) release, generated following oxidative (hydrogen peroxide) and inflammatory (tumor necrosis factor α, interleukin-1β, and lipopolysaccharide) stimulation. The obtained promising results suggest potential protective role of nsLTP2 in vascular diseases prevention. PRACTICAL APPLICATION: nsLTP 2 peptide is resistant to proteases throughout the gastrointestinal tract and exerts antioxidant and cytoprotective activities. These characteristics could be exploited in vascular diseases prevention.

Published
2017

45. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up

Author

Sensi, M., Cossu, G., Mancini, F., Pilleri, M., Zibetti, M., Modugno, N., Quatrale, R., Tamma, F., Antonini, A., Aguggia, M., Amboni, M., Arca, R., Bartolomei, L., Bonetto, N., Calandra-Buonaura, G., Bove, F., Calandrella, D., Canesi, M., Cannas, A., Capecci, M., Caputo, E., Ceravolo, M. G., Ceravolo, R., Cerrone, G., Coletti Moja, M., Comi, C., Cortelli, P., D'Antonio, P., Dematteis, F., Di Lazzaro, V., Eleopra, R., Fabbrini, G., Fichera, M., Grassi, E., Guido, M., Gusmaroli, G., Latorre, A., Malaguti, M. C., Marano, M., Marano, P., Marconi, R., Mazzucchi, S., Meco, G., Minafra, B., Morgante, F., Pacchetti, C., Pierantozzi, M., Pontieri, F. E., Riboldazzi, G., Ricchi, V., Ricchieri, G., Rinaldo, S., Rispoli, V., Rossi, S., Rubino, A., Russo, A., Saddi, M. V., Stefani, A., Simoni, S., Solla, P., Tambasco, N., Tamburin, S., Tessitore, A., Torre, E., Ulivelli, M., Vita M., Gi, Volonté, M. A., on behalf of the, ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP, Sensi, M., Cossu, G., Mancini, F., Pilleri, M., Zibetti, M., Modugno, N., Quatrale, R., Tamma, F., Antonini, A., Aguggia, M., Amboni, M., Arca, R., Bartolomei, L., Bonetto, N., Calandra-Buonaura, G., Bove, F., Calandrella, D., Canesi, M., Cannas, A., Capecci, M., Caputo, E., Ceravolo, M. G., Ceravolo, R., Cerrone, G., Coletti Moja, M., Comi, C., Cortelli, P., D'Antonio, P., Dematteis, F., Di Lazzaro, V., Eleopra, R., Fabbrini, G., Fichera, M., Grassi, E., Guido, M., Gusmaroli, G., Latorre, A., Malaguti, M. C., Marano, M., Marano, P., Marconi, R., Mazzucchi, S., Meco, G., Minafra, B., Morgante, F., Pacchetti, C., Pierantozzi, M., Pontieri, F. E., Riboldazzi, G., Ricchi, V., Ricchieri, G., Rinaldo, S., Rispoli, V., Rossi, S., Rubino, A., Russo, A., Saddi, M. V., Stefani, A., Simoni, S., Solla, P., Tambasco, N., Tamburin, S., Tessitore, A., Torre, E., Ulivelli, M., Vita, M. G., Volonte, M. A., Sensi, Mariachiara, Cossu, Giovanni, Mancini, Francesca, Pilleri, Manuela, Zibetti, Maurizio, Modugno, Nicola, Quatrale, Rocco, Tamma, Filippo, Antonini, Angelo, Italian Levodopa Carbidopa Intestinal Gel Working Group [.., Calandra-Buonaura, Giovanna, Cortelli, Pietro, and ]

Subjects
Male, 0301 basic medicine, Pediatrics, Neurology, Parkinson's disease, Longitudinal Studie, Pharmacology, Antiparkinson Agents, Levodopa, 0302 clinical medicine, Retrospective Studie, Weight loss, Drug Combination, levodopa-carbidopa intestinal gel infusion, neuropathy, parkinson's disease, withdrawal, Longitudinal Studies, Gel, Carbidopa, Parkinson Disease, Health Survey, Intestine, Substance Withdrawal Syndrome, Intestines, Drug Combinations, Italy, Antiparkinson Agent, Withdrawal, Disease Progression, Female, Settore MED/26 - Neurologia, medicine.symptom, Human, medicine.drug, medicine.medical_specialty, Levodopa-carbidopa intestinal gel infusion, Neuropathy, Geriatrics and Gerontology, Neurology (clinical), 03 medical and health sciences, medicine, Humans, Adverse effect, Retrospective Studies, business.industry, Retrospective cohort study, Gels, Health Surveys, medicine.disease, Comorbidity, Discontinuation, 030104 developmental biology, business, 030217 neurology & neurosurgery
Abstract

Objectives To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy. Methods Sixty Parkinson's Disease (PD) specialists in Italy were invited to complete a survey covering issues on clinical and practical aspects of LCIG therapy. Results Clinical features of 905 patients were collected retrospectively. The majority of centres reported the use of a multidisciplinary team, biochemistry testing, neurophysiological and neuropsychological tests before and after treatment, in addition to caregivers' training and patient's follow as outpatients. Most centres (60%) used internal guidelines for patient selection. The overall rate of adverse events was 55.1%. Weight loss, chronic polyneuropathy and stoma infection were the most frequently reported. 40% of centres used replacement therapy with Vitamin B12 and Folic acid from the start of LCIG and continued this for the duration of treatment. The rate of discontinuation was of 25.7% overall, with 9.5% of cases occurring in the first year. The main causes of withdrawal were device-related complications, disease progression (comorbidity, severe dementia) and caregiver and/or patient dissatisfaction. Conclusions In Italy LCIG infusion is managed in a uniform manner at a clinical, practical and organizational level even though the selection criteria are not standardized through the country. The high percentage of patients remaining on treatment in the short- and long-term follow-up confirms effectiveness of treatment, careful follow-up, and appropriate patient and caregivers training.

Published
2017

47. Le sfide che non possiamo ignorare

Author

DORIA G, MALAGUTI M, Malaguti, Maria Chiara, MALAGUTI M (ORCID:0000-0003-2445-8529), DORIA G, MALAGUTI M, Malaguti, Maria Chiara, and MALAGUTI M (ORCID:0000-0003-2445-8529)

Abstract

Nowadays the classical conceptualization of international law undercomes challenges and we need to rethink premises

Published
2016

48. Software use cases to elicit the software requirements analysis within the ASTRI project

Author

Conforti, and Antolini, V., and Bonnoli, E., and Bruno, G., and Bulgarelli, P., and Capalbi, A., and Fioretti, M., and Fugazza, V., and Gardiol, D., and Grillo, D., and Leto, A., and Lombardi, G., and Lucarelli, S., and MacCarone, F., and Malaguti, M. C., and Pareschi, G., and Russo, G., and Sangiorgi, F., and Schwarz, P., and Scuderi, J., and Tanci, S., Tosti, Gino, And, Trifoglio, and Vercellone, M., and Sanchez, S., and R. Z.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results